Evidence map›Paper›PMID 19692474›Full record

ArticleJournal of virology2009

X4 human immunodeficiency virus type 1 gp120 down-modulates expression and immunogenicity of codelivered antigens.

Avi-Hai Hovav, Michael Santosuosso, Maytal Bivas-Benita, Andre Plair, Alex Cheng, Mazal Elnekave, Elda Righi, Tao Chen, Satoshi Kashiwagi, Michael W Panas and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by Δ9-Tetrahydrocannabinol.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2015
    Article
  3. Article
  4. Article
  5. Journal of clinical & cellular immunology · 2013
    Article
  6. Article
  7. Article
  8. A shift from cell cultures to creatures: in vivo imaging of small animals in experimental regenerative medicine.Molecular therapy : the journal of the American Society of Gene Therapy · 2011
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Avi-Hai HovavInstitute of Dental Sciences, Hebrew University-Hadassah Faculty of Dental Medicine, P.O. Box 122722, Jerusalem 91120, Israel. avihaih@ekmd.huji.ac.il
Michael Santosuosso
Maytal Bivas-Benita
Andre Plair
Alex Cheng
Mazal Elnekave
Elda Righi
Tao Chen
Satoshi Kashiwagi
Michael W Panas
Shi-Hua Xiang
Karina Furmanov
Norman L Letvin
Mark C Poznansky
Harvard University · USMassachusetts General Hospital · USHebrew University of Jerusalem · ILBeth Israel Deaconess Medical Center · USDana-Farber Cancer Institute · US

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI BHARDWAJ, NINA · 2006 to 2011
$290.5M
Viral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F · 2005 to 2005
$14.9M
HIV-1 gp120 induced CTL chemorepulsion:dysregulation of migration & localizationR01AI049757 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI POZNANSKY, MARK COLEMAN · 2001 to 2010
$4.0M
NIAID NIH HHS AI067854NIAID NIH HHS R01 AI049757NIAID NIH HHS R01 AI49757NIAID NIH HHS U01 AI067854NIAID NIH HHS U19 AI067854
6 · The paper itself

Abstract

In order to increase the immune breadth of human immunodeficiency virus (HIV) vaccines, strategies such as immunization with several HIV antigens or centralized immunogens have been examined. HIV-1 gp120 protein is a major immunogen of HIV and has been routinely considered for inclusion in both present and future AIDS vaccines. However, recent studies proposed that gp120 interferes with the generation of immune response to codelivered antigens. Here, we investigate whether coimmunization with plasmid-encoded gp120 alters the immune response to other coadministered plasmid encoded antigens such as luciferase or ovalbumin in a mouse model. We found that the presence of gp120 leads to a significant reduction in the expression level of the codelivered antigen in vivo. Antigen presentation by antigen-presenting cells was also reduced and resulted in the induction of weak antigen-specific cellular and humoral immune responses. Importantly, gp120-mediated immune interference was observed after administration of the plasmids at the same or at distinct locations. To characterize the region in gp120 mediating these effects, we used plasmid constructs encoding gp120 that lacks the V1V2 loops (DeltaV1V2) or the V3 loop (DeltaV3). After immunization, the DeltaV1V2, but not the DeltaV3 construct, was able to reduce antigen expression, antigen presentation, and subsequently the immunogenicity of the codelivered antigen. The V3 loop dependence of this phenomenon seems to be limited to V3 loops known to interact with the CXCR4 molecule but not with CCR5. Our study presents a novel mechanism by which HIV-1 gp120 interferes with the immune response against coadministered antigen in a polyvalent vaccine preparation.

Indexed as

AIDS VaccinesAmino Acid SequenceAnimalsAntibody FormationAntigen PresentationAntigen-Presenting CellsApoptosisFemaleHIV-1HIV AntigensHIV Envelope Protein gp120HIV InfectionsHumansImmunizationMiceMice, Inbred BALB CAIDS Vaccinesgp120 protein, Human immunodeficiency virus 1HIV AntigensHIV Envelope Protein gp120HIV envelope protein gp120 (305-321)OvalbuminPeptide Fragments

Identifiers

PMID19692474
PMCPMC2772807
OpenAlexW2159891894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.